FHTX — Foghorn Therapeutics. Share Price
0.000.00%
Last trade - 00:00- $225.60m
- -$8.46m
- $34.16m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.61 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -47.44% | ||
| Return on Equity | n/a | ||
| Operating Margin | -315.93% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.43 | 1.32 | 19.23 | 34.16 | 29.22 | 34.16 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company engaged in developing medicines that modulate gene expression through selectively targeting the chromatin regulatory system for therapeutic intervention in oncology. Its Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within the system. The Company’s Traffic Control platform discovers and develops drugs in oncology and other therapeutic areas, including virology, autoimmune disease and neurology. The Company is developing FHD-286, a selective, allosteric ATPase inhibitor and which is evaluating two separate Phase I studies in metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia, and myelodysplastic syndrome. It is also developing FHD-909 a highly potent, allosteric and orally available small molecule.
Directors
- Adrian Gottschalk CEO (45)
- Allan Reine CFO (46)
- Steven Bellon CSO
- Samuel Agresta OTH (49)
- Michael LaCascia OTH (56)
- Cigall Kadoch DRC (35)
- Ian Smith DRC (55)
- Scott Biller IND (65)
- Douglas Cole IND (60)
- Balkrishan Gill IND (56)
- Adam Koppel IND (51)
- Michael Mendelsohn IND (65)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 2nd, 2015
- Public Since
- October 23rd, 2020
- No. of Shareholders
- 29
- No. of Employees
- 116
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 42,565,904
- Address
- 500 Technology Square, Suite 700, CAMBRIDGE, 02139
- Web
- https://foghorntx.com/
- Phone
- +1 6175863100
- Contact
- Gregory Dearborn
- Auditors
- Deloitte & Touche LLP
Upcoming Events for FHTX
Q2 2024 Foghorn Therapeutics Inc. Earnings Release
Similar to FHTX
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Foghorn Therapeutics. share price?
As of Today at 19:08 UTC, shares in Foghorn Therapeutics. are trading at $5.30. This share price information is delayed by 15 minutes.
How has the Foghorn Therapeutics. share price performed this year?
Shares in Foghorn Therapeutics. last closed at $5.30 and the price had moved by -27.3% over the past 365 days. In terms of relative price strength the Foghorn Therapeutics. share price has underperformed the S&P500 Index by -39.5% over the past year.
What are the analyst and broker recommendations for Foghorn Therapeutics.?
The overall consensus recommendation for Foghorn Therapeutics. is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Foghorn Therapeutics. dividend yield?
Foghorn Therapeutics. does not currently pay a dividend.
Does Foghorn Therapeutics. pay a dividend?
Foghorn Therapeutics. does not currently pay a dividend.
When does Foghorn Therapeutics. next pay dividends?
Foghorn Therapeutics. does not currently pay a dividend.
How do I buy Foghorn Therapeutics. shares?
To buy shares in Foghorn Therapeutics. you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Foghorn Therapeutics.?
As of the previous close price of $5.30, shares in Foghorn Therapeutics. had a market capitalisation of $225.60m.
Where are Foghorn Therapeutics. shares listed?
Here are the trading details for Foghorn Therapeutics.:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: FHTX
What kind of share is Foghorn Therapeutics.?
Based on an overall assessment of its quality, value and momentum Foghorn Therapeutics. is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Foghorn Therapeutics. share price forecast for 2024?
The analyst consensus target price for shares in Foghorn Therapeutics. is $13.75. That is 159.43% above the last closing price of $5.30.
Analysts covering Foghorn Therapeutics. currently have a consensus Earnings Per Share (EPS) forecast of -$2.13 for the next financial year.
What is the trend in the Foghorn Therapeutics. share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Foghorn Therapeutics.. Over the past six months, its share price has outperformed the S&P500 Index by +53.05%.
As of the last closing price of $5.30, shares in Foghorn Therapeutics. were trading -10.48% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Foghorn Therapeutics. PE Ratio?
The Foghorn Therapeutics. PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Foghorn Therapeutics.?
Foghorn Therapeutics.'s management team is headed by:
- Adrian Gottschalk - CEO
- Allan Reine - CFO
- Steven Bellon - CSO
- Samuel Agresta - OTH
- Michael LaCascia - OTH
- Cigall Kadoch - DRC
- Ian Smith - DRC
- Scott Biller - IND
- Douglas Cole - IND
- Balkrishan Gill - IND
- Adam Koppel - IND
- Michael Mendelsohn - IND